CancerDrs Find care

Stomach Cancer clinical trials in New Mexico

10 actively recruiting stomach cancer trials at 5 sites across New Mexico.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in New Mexico:
  • Lovelace Medical Center-Saint Joseph Square — Albuquerque, New Mexico
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, a…

Sponsor: AstraZeneca
NCT ID: NCT06764875
Sites in New Mexico:
  • Research Site — Santa Fe, New Mexico
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're …

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT06157892
Sites in New Mexico:
  • San Juan Oncology Associates — Farmington, New Mexico
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in New Mexico:
  • Research Site — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combinat…

Sponsor: Linnaeus Therapeutics, Inc.
NCT ID: NCT04130516
Sites in New Mexico:
  • University of New Mexico Comprehensive Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.

Sponsor: Coherus Oncology, Inc.
NCT ID: NCT06657144
Sites in New Mexico:
  • Christus St Vincent Regional Medical Center — Santa Fe, New Mexico
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New Mexico:
  • Lovelace Medical Center-Saint Joseph Square — Albuquerque, New Mexico
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
  • Lovelace Women's Hospital — Albuquerque, New Mexico
  • Presbyterian Kaseman Hospital — Albuquerque, New Mexico
  • Memorial Medical Center-Las Cruces — Las Cruces, New Mexico
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New Mexico:
  • Massive Bio SYNERGY-AI site — Albuquerque, New Mexico
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20